FDA Authorizes New Injection for Chronic Hepatitis B

The FDA has approved Hibsago (bepirovirsen), an injection for chronic hepatitis B virus (HBV) infection in certain adults without cirrhosis. This treatment is for patients who have been on existing antiviral therapy for at least six months with suppressed HBV levels and specific surface antigen levels. Clinical trials demonstrated that 24% of Hibsago recipients met criteria to discontinue prior medication, offering a new therapeutic option for managing chronic HBV.